InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Appendix 4G and Corporate Governance Statement 26 Oct 2016 5:18PM $0.043 $0.420 risen by 876.74%
$18 Annual Report 2016 26 Oct 2016 8:58AM $0.043 $0.420 risen by 876.74%
$18 Notice of Annual General Meeting/Proxy Form 25 Oct 2016 7:35PM $0.043 $0.420 risen by 876.74%
$18 Appendix 3Y - Change of Director's Interest Notice x 3 21 Oct 2016 1:56PM $0.045 $0.420 risen by 833.33%
$18 Issue of Performance Rights - Appendix 3B 17 Oct 2016 7:44PM $0.048 $0.420 risen by 775%
$18 Listed Options now Quoted - ASX Code MXCOD 11 Oct 2016 9:39AM $0.046 $0.420 risen by 813.04%
$18 Issue of Listed Options from Capital Raisings - Appendix 3B 6 Oct 2016 1:40PM $0.046 $0.420 risen by 813.04%
$18 Operations Update - Multiple Revenue Streams Imminent 29 Sep 2016 12:32AM $0.041 $0.420 risen by 924.39%
$18 Results of General Meeting 27 Sep 2016 7:20PM $0.040 $0.420 risen by 950%
$18 New Med Cannabis White Paper Developed with Uni of Sydney 21 Sep 2016 10:04AM $0.042 $0.420 risen by 900%
$18 Cleansing Prospectus Closed - No Shares Issued 7 Sep 2016 6:16PM $0.042 $0.420 risen by 900%
$18 Cleansing Prospectus 6 Sep 2016 6:16PM $0.041 $0.420 risen by 924.39%
$18 Strategic Agreement signed with Epilepsy Action Australia 1 Sep 2016 1:06PM $0.041 $0.420 risen by 924.39%
$18 Q&A with Nativ Segev, MGC Pharmaceuticals Managing Director 30 Aug 2016 10:14AM $0.042 $0.420 risen by 900%
$18 Appendix 4E and Audited 2016 Financial Report 29 Aug 2016 1:29PM $0.041 $0.420 risen by 924.39%
$18 Notice of General Meeting/Proxy Form 26 Aug 2016 5:46PM $0.041 $0.420 risen by 924.39%
$18 Psoriasis and Acne Tests Advancing Ahead of Product Launch 23 Aug 2016 11:50AM $0.041 $0.420 risen by 924.39%
$18 Appendix 3B - Issue of Consultant Shares 12 Aug 2016 5:21PM $0.046 $0.420 risen by 813.04%
$18 Sale of Lingokoto and Bouroubourou Gold Exploration Assets 11 Aug 2016 9:56AM $0.049 $0.420 risen by 757.14%
$18 June Quarterly Activity and Cashflow Report 28 Jul 2016 12:37AM $0.050 $0.420 risen by 740%
$18 Q&A with Dr Ross Walker, MGC Pharmaceuticals Director 20 Jul 2016 12:38PM $0.048 $0.420 risen by 775%
$18 Leading Epilepsy Expert Joins MXC Strategic Advisory Board 13 Jul 2016 10:02AM $0.047 $0.420 risen by 793.62%
$18 First Revenues Received from Californian Cosmetics Deal 27 Jun 2016 9:31AM $0.042 $0.420 risen by 900%
$18 Resignation of Director - Appendix 3Z 24 Jun 2016 5:39PM $0.042 $0.420 risen by 900%
$18 Appendix 3B - Option Conversion 23 Jun 2016 6:24PM $0.046 $0.420 risen by 813.04%

726 - 750 of 818 results

Page 30 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.